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The differentiation of stem cells is a fundamental process in cell biology and
understanding its mechanism might open a new avenue for therapeutic strat-
egies. Using an ex vivo co-culture system consisting of human primary haema-
topoietic stem and progenitor cells growing on multipotent mesenchymal
stromal cells as a feeder cell layer, we describe here the exosome-mediated
release of small membrane vesicles containing the stem and cancer stem cell
marker prominin-1 (CD133) during haematopoietic cell differentiation. Surpris-
ingly, this contrasts with the budding mechanism underlying the release of this
cholesterol-binding protein from plasma membrane protrusions of neural pro-
genitors. Nevertheless, in both progenitor cell types, protein–lipid assemblies
might be the essential structural determinant in the release process of prominin-
1. Collectively, these data support the concept that prominin-1-containing lipid
rafts may host key determinants necessary to maintain stem cell properties and
their quantitative reduction or loss may result in cellular differentiation.
INTRODUCTION
The process of cell differentiation is an important issue in stem
cell biology and understanding its mechanism might allow us to
manipulate the fate of primitive cells thus opening novel
modalities for stem cell-based therapies. This is particularly true
for haematopoietic stem and progenitor cells (HSPCs), which
have the capacity to self-renew and the ability to differentiate
into mature blood cells, enabling them to repopulate the bone
marrow upon their clinical transplantation. The exclusion of
molecular determinants necessary to maintain stem cell
properties is hypothesized to be a key aspect underlying the
cell differentiation mechanism, potentially leading to the
differentiation process.
Thirteen years ago, a novel cholesterol (Ch)-interacting,
pentaspan membrane glycoprotein, named prominin-1 (CD133)
has been identiﬁed as a surface marker of both neural
(Weigmann et al, 1997) and haematopoietic (Yin et al, 1997)
stem and progenitor cells. Since numerous somatic stem cells
and cancer stem cells originating from different organ systems
have been demonstrated to express it, prominin-1 might
become—among other things—a biological tool for stem cell
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(Fargeas et al, 2006; O’Brien et al, 2007; Singh et al, 2004;
Vander Griend et al, 2008). In both epithelial and non-epithelial
cell types, prominin-1 is speciﬁcally localized to plasma
membrane protrusions, e.g. microvilli (Bauer et al, 2008;
Corbeil et al, 2000; Weigmann et al, 1997), by a mechanism
involving Ch-based membrane microdomains (lipid rafts;
Gillette et al, 2009; Ro ¨per et al, 2000). Although its physiological
function in stem cells remains elusive, we have previously
observed that during the cell division of neural and HSPCs
prominin-1 was either symmetrically or asymmetrically dis-
tributed between the two nascent daughter cells (Bauer et al,
2008; Fargeas et al, 2006; Kosodo et al, 2004). Its association
with lipid rafts, which are known to play a role in signal
transduction (Simons & Toomre, 2000), is particularly inter-
esting in this context. Prominin-1-containing lipid rafts might
hostkeydeterminantsorplayersnecessarytomaintainstemcell
properties—their quantitative reduction or loss might result in
differentiation (Fargeas et al, 2006; Marzesco et al, 2005). In
agreement with this, Kosodo et al could demonstrate that
neurogenic cell divisions of neural progenitors, but not
proliferative ones, involve such an asymmetric distribution of
prominin-1 (Kosodo et al, 2004).
Additionally, we could show that in the developing
embryonic mouse brain, prominin-1 is released from neural
progenitor cells into the lumen of the neural tube during the
early phase of neurogenesis (Marzesco et al, 2005). Therein,
prominin-1 is associated with small (50–80nm) membrane
vesicles that were distinct from exosomes and appeared to bud
from microvilli and/or primary cilium (Dubreuil et al, 2007;
Marzesco et al, 2005). Such prominin-1-containing membrane
vesicles (prominin-1-CMV) were also found in human cerebral
ﬂuids, and remarkably appear to be up-regulated in glioblas-
toma patients suggesting that putative cancer stem cells might
release them as well (Huttner et al, 2008).
Does a similar phenomenon exist in other stem cell type or is
it unique to those derived from the neural system? Is the release
of prominin-1-CMV a read out of differentiation in general?
Here, we have addressed these issues using an established ex
vivo co-culture system consisting of primary HSPCs growing on
multipotent mesenchymal stromal cells (MSCs) as a feeder cell
layerinacytokine-drivenprotocolasacellularmodel(Freundet
al, 2006). Our data demonstrate that HSPCs also release
prominin-1 during their differentiation but the cellular mechan-
ismunderlyingitappearstobedistinctfromtheoneoccurringin
neural progenitors (Dubreuil et al, 2007; Marzesco et al, 2005).
Finally, upon release, prominin-1-CMV could be internalized by
feeder cells suggesting a potential role in intercellular commu-
nication.
RESULTS
Primary haematopoietic stem cells release prominin-1-
containing membrane vesicles
To determine whether HSPCs release the stem cell marker
prominin-1 as previously reported for neural progenitors
(Corbeil et al, 2010), the 1-week-old conditioned co-culture
HSPC/MSC medium was collected and then subjected to
differential centrifugation followed by immunoblotting of the
recovered pellets for prominin-1. As expected, a 120-kDa
prominin-1-immunoreactive band was detected in the 300 g
pellet fraction that contains prominin-1-positive HSPCs (Fig 1A,
prominin-1, arrow). Interestingly, prominin-1 immunoreactiv-
ity was also observed in the 200,000 g pellet (Fig 1A,
prominin-1, arrow). No or little immunoreactivity was detected
intheotherfractions,i.e.the1200,10,000and400,000 gpellet
(Fig 1A, prominin-1). The association of prominin-1 with the
200,000 g pellet appears speciﬁc since CD34 was not detected
(Fig 1A, CD34, arrowhead, n¼3). Upon further fractionation by
equilibrium sucrose gradient centrifugation (0.1–1.2M), the
prominin-1-containing 200,000 g pellet (as revealed by
immunoblotting) was found in a peak of relatively low buoyant
density(Fig1B, Fraction4–6,1.07g/ml,arrow)similartothatof
exosomes or synaptic vesicles (Huttner et al, 1983; The ´ry et al,
2002). Only a limited amount was detected in the pellet fraction
(Fig 1B, P, arrow).
To assess the nature of the material associated with the
200,000 g pellet, an electron microscopy (EM) analysis was
undertaken. This revealed the presence of small membrane
vesicles with an approximate diameter of 40–80nm (Fig 1C and
D, arrows) and larger electron-dense membrane structures with
a diameter range of 200–600nm (Fig 1D, arrowhead). Following
immunogold labelling of prominin-1, both the smaller mem-
branevesiclesandthelarger membranestructures werepositive
(Fig 1E). The latter may correspond to the prominin-1-
immunoreactive materials found in the pellet fraction of
equilibrium sucrose density gradient (Fig 1B, P). Such larger
structures are similar in size to a heterogeneous microvesicle
population (100nm to 1mm) previously described to be derived
from theplasmamembrane (Ratajczak etal, 2006). Notall small
membrane vesicles were immunolabelled (Supporting Informa-
tion Fig S1A–C). Furthermore, the material associated with
200,000 g pellet were positive for CD63 (Supporting Informa-
tion Fig S1D), a tetraspan membrane protein highly enriched in
exosomes from virtually any cell type (The ´ry et al, 2002),
indicating the presence of such vesicles in this fraction as
expected from their relative low buoyant density (see above).
We next addressed whether prominin-1 associated with
200,000 g pellet-derived membrane vesicles is differentially
extractable in certain non-ionic detergents (Triton X-100 vs.
Lubrol WX) as previously described for microvillar-associated
ones (Ro ¨per et al, 2000) indicating its potential association with
a given subset of lipid rafts (Pike, 2004). Upon lysis of whole
HSPC fractions from 1-week-old co-culture with either 0.5%
Triton X-100 or Lubrol WX for 30min at 48C, prominin-1 was
found to be completely soluble in Triton X-100 after centrifuga-
tion for 1h at 100,000 g (Fig 1F, Cells, Triton-100, S, arrow),
while interestingly being partly insoluble in Lubrol WX (Fig 1F,
Cells, Lubrol WX, P, arrow) as previously shown in epithelial
cells (Ro ¨per et al, 2000). When the association of prominin-1
with detergent-resistant membrane complexes was investigated
with HSPC-derived vesicles along the same lines as for the cells,
a similar phenomenon could be observed (Fig 1F, 200,000 g
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prominin-1 is partly associated with Lubrol WX-insoluble
membranecomplexes inbothHSPCsandthederived membrane
vesicles. Lipid rafts are enriched in Ch and sphingomyelin (SM;
Brown & London, 2000). In order to further dissect the lipid
compositionofprominin-1-containing HSPC-derivedmembrane
vesicles, we analysed them by thin layer chromatography (TLC)
following C
14-acetate labelling for 3 days. By comparison to
haematopoietic cells (Fig 1G, Cells), which reveal a  25% Ch
and  9% SM content of the total lipid composition, the
prominin-1-immunoprecipitated vesicle fraction (Fig 1G, pro-
minin-1-CMV) appears enriched in Ch and SM with  37 and
 19%, respectively, thus indicating a distinct lipidic composi-
tion compared to the membranes of origin.
Association of prominin-1 with exosomes
To morphologically determine the source of prominin-1-CMV,
we re-investigated the prominin-1 localization within the MSC-
adherent HSPC population by indirect (differential) immuno-
ﬂuorescence microscopy. As originally described (Freund et al,
2006), the cell surface labelling revealed preferential localiza-
tion of prominin-1 in various plasma membrane protrusions,
e.g. leading edge of magnupodium or lamellipodium (Fig 2A,
red, arrow). In cells with a round morphology, prominin-1 is
often concentrated in one pole (Fig 2A, red, arrow)—previously
described to be enriched in microvillar-like structures (Bauer et
al, 2008; Freund et al, 2006). Remarkably, a second round of
labelling performed upon cell permeabilization revealed an
additional, intracellular staining of prominin-1 (Fig 2A, green).
Thus, two distinct pools of prominin-1 molecules co-exist in
haematopoietic cells. Note that in rare cases, only an
intracellular or a cell surface staining of prominin-1 could be
detected (Supporting Information Fig S2). To gain more insight
into the intracellular pool, we double-labelled cells with
different cytoplasmic organelle markers. Neither GM130,
TGN46 nor BODIPY showed a signiﬁcant co-localization with
prominin-1 suggesting the exclusion of the latter from the cis-
Golgi apparatus, the trans-Golgi network and lipid droplets,
respectively (Supporting Information Fig S3). Interestingly, a
partial localization of prominin-1 with either early endosomal
antigen 1 (EEA1) or Smad anchor forreceptor activation (SARA)
could be observed (Supporting Information Fig S4), indicating
that a minute fraction of prominin-1 is associated with the early
and/or signalling endosomal compartment (Bo ¨kel et al, 2006).
Furthermore, a signiﬁcantly overlapping signal was observed
with CD63 indicating the potential association of prominin-1
with exosomal-like structures (Fig 2B). To address this issue in
detail, we performed an EM analysis. Surprisingly, we could
visualize prominin-1 not only in plasma membrane protrusions
as previously reported (Corbeil et al, 2000; Fig 2C, arrow) but
also in small intraluminal membrane vesicles within multi-
vesicular bodies (Fig 2C, see inset, arrowheads). Under our
experimental conditions, not all of them were immunolabelled,
which is in agreement with the data obtained with membrane
vesicles found in the 200,000 g pellet (Fig 1 and Supporting
Information Fig S1). As expected, multivesicular bodies were
labelled with an anti-CD63 antibody (Fig 2D, arrowheads).
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Figure 1. Association of prominin-1, but not CD34, with lipid raft-
membrane vesicles released by HSPCs.
A. One-week-oldco-culture HSPC/MSC conditioned medium wassubjected
to differential centrifugation for 5min at 300 g, 20min at 1200 g,
30min at 10,000 g, 60min at 200,000 g and 60min at 400,000 g.
The resulting pellets were analysed by immunoblotting for either pro-
minin-1 (top panel, arrow) or CD34 (bottom panel, arrowhead). Proteins
in the 400,000 g supernatant (Sup.) were analysed in parallel.
B. The 200,000 g pellet recovered after differential centrifugation (panel
A) was subjected to equilibrium sucrose gradient (0.1–1.2M) centrifu-
gation. Equal volumes of the recovered fractions and the pellet were
analysed by immunoblotting for prominin-1 (arrow).
C,D. Negative EM analysis of the 200,000 g pellet revealed the presence of
small membrane vesicles ( 40–80nm; arrows) and larger dense
structures ( 200–600nm; arrowhead).
E. Negative staining EM of prominin-1 immunogold-labelled membrane
vesicles recovered in the 200,000 g pellet. Scale bars, 100nm [(C–E)].
F. Haematopoietic cells (Cells) growing for 1 week in the co-culture system
and 200,000 g pellets (200,000 g pellet) recovered upon differential
centrifugation (panel A) were lysed for 30min at 48C in either 0.5%
Triton X-100 or Lubrol WX or without detergent (PBS) and centrifuged
for 60min at 100,000 g. The resulting supernatants (S) and pellets (P)
were analysed by immunoblotting for prominin-1 (arrows).
G. Lipid composition analysis of prominin-1-CMV was performed by C
14-
acetate labelling of HSPCs co-cultured with MSCs followed by TLC
analysis of either haematopoietic cells (Cells) or the released prominin-
1-positive vesicles recovered by a paramagnetic isolation with mAb
CD133 (prominin-1-CMV). Percentages of cholesterol (Ch) and sphin-
gomyelin (SM) of the total lipid composition are indicated.  , sample
loading point.
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HSPC-derived prominin-1-positive vesicles, we performed anti-
prominin-1 immuno-afﬁnity isolation and analysed vesicle
contents by immunoblotting for speciﬁc markers. Interestingly,
in addition to prominin-1 (Supporting Information Fig S5;
prominin-1, top panel, arrow), we could observe, three other
molecules reported to be associated with exosomes; ﬂotillin-1,
ﬂotillin-2 (Supporting Information Fig S5; middle panels, arrow)
and the cytoplasmic PDZ-domain protein syntenin (Supporting
Information Fig S5; bottom panel, arrow). The latter was only
detectable in a limited amount in the prominin-1-positive vesicle
fraction. Syntenin has been shown to be a major protein
constituentofdendriticcell-derivedexosomes(The ´ryetal,2001).
Release of prominin-1-containing membrane vesicles during
the differentiation process
Is the release of prominin-1-CMV concomitant with HSPC
differentiation? To answer this question, we analysed the relative
amount of prominin-1-CMV released by HSPCs with time in
culture by immunoblotting (Fig 3A). HSPCs were co-cultured for
4, 9 and 14 days. Interestingly, we could observe that over
different time periods, the number of prominin-1-positive HSPCs
initiallyincreasedasdeterminedbyﬂowcytometry(fromday4to
9;Fig3B,prominin-1-positiveHSPC),whichwasalsoreﬂectedby
prominin-1 immunoreactivity detected in 300 g pellet (Fig 3A,
compare top and middle panels, respectively), and then
decreased (from days 9 to 14; Fig 3B, prominin-1-positive HSPC).
Inparalleltothisdecrease,therelativeamountoftheprominin-1-
CMV recovered in the 200,000 g pellet remarkably increased
(Fig 3A and B, ratio of 200,000 g/300 g). A similar
phenomenon was observed using 5- or 10-days time windows
(Fig 3C and D). In addition to the full-length prominin-1 detected
in cells (300 g pellet), but not in 200,000 g pellet fraction,
additional faster migrating prominin-1-immunoreactive bands
can be observed (Fig 3A, middle and bottom panels) suggesting
its intracellular degradation. Finally, it could be observed that, in
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Figure 2. Two pools of prominin-1 co-exist in
HSPCs.
A. HSPCs growing for 1 week on MSCs were first
cell surface-labelled for prominin-1 prior to
PFA fixation and saponin-permeabilization
followed by a second round of prominin-1
labelling. The nuclei were stained with Hoechst
(blue). The labelled cells were analysed using
confocal laser scanning microscopy. A compo-
site of 16 optical sections of HSPCs exhibiting
various morphologies as indicated are shown.
Note that prominin-1 is not only found at the
cell surface (red, arrows) but also in intra-
cellular compartments (green) of the HSPCs.
DIC, differential interference contrast.
B. Partial co-localization of prominin-1 and
endosomal/lysosomal/exosomal marker CD63.
PFA-fixed, saponin-permeabilized HSPCs
growing on MSCs were double-immunola-
belled for prominin-1 (red) and CD63 (green)
followed by appropriate secondary antibodies
and observed by confocal laser scanning
microscopy. Nuclei were visualized with
Hoechst (blue). A single optical x–y-plane
section revealed that prominin-1 and CD63
partially co-localized in intracellular struc-
tures.Ahighmagnificationviewisshowninthe
corresponding inset.
C,D. Negative staining EM of prominin-1 (C) or
CD63 (D) immunogold labelled HSPCs followed
by silver enhancement (C) revealed the local-
ization of prominin-1 in either small mem-
brane vesicles present within multivesicular
bodies (C,see inset, arrowheads) or microvillar-
like structures present at the cell surface (C,
arrow). (C) The red box in the left panel
demarcates the region displayed at higher
magnification in the right panel. The multi-
vesicular bodies were also labelled with CD63
(D).Notethat themembranous structures were
not well preserved due to saponin-permeabi-
lization (C) prior the labelling procedure. Scale
bars, 10mm [(A) and (B)], 0.5mm [(C) and (D)].
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relative expression of differentiation markers such as CD42b and
CD61 increased (Fig 4). Under these culture conditions less than
2% (i.e. after 9 days, 0%; after 14 days, 2%; n¼320 cells)
prominin-1-positive HSPCs stained positive for annexin V
indicating that apoptosis is not the underlying mechanism of
the release of prominin-1-CMV, which is in line with the general
resistance of prominin-1-positive cells to apoptosis (Chiou et al,
2008; Zobalova et al, 2008).
Could we provoke the release of prominin-1-CMV? We have
addressed this question by stimulating HSPC differentiation
using phorbol esters such as phorbol 12-myristate 13-acetate
(PMA) as previously reported (Rossi et al, 1996). HSPCs
cultivatedonMSCsforonly2dayswereexposedfor3additional
days to 160nM PMA prior to differential centrifugation.
Interestingly, the amount of prominin-1 immunoreactivity
recovered in the 200,000 g pellet fraction (vesicles) signiﬁ-
cantly increased under differentiation condition, whereas, its
fraction in the 300 g pellet (cells) decreased (Fig 5, panel A vs.
panel B). In contrast to prominin-1, neither actin nor a-tubulin
were recovered in the 200,000 g pellet (Fig 5), which rules out
both fragmentation of plasmamembrane protrusions (e.g. actin-
based microvillus) and relics of cytokinesis (tubulin-based) in
this fraction. The very small amount of prominin-1 in the 1200
and 10,000 g pellets might nevertheless derive from such
membranes (see also Fig 3A; Dubreuil et al, 2007; Giebel &
Beckmann, 2007). Similar results were obtained when HSPCs
were growing on a ﬁbronectin-coated plastic surface instead of
MSCs thus excluding potential side effects of feeder cells (Fig 5A
and B). In parallel, the differentiation of HSPCs induced by PMA
was monitored based on the expression of typical stem or
differentiated CD markers using either microscopy or ﬂow
cytometry (for details see Legend of Supporting Information Fig
S6). As expected, the number of prominin-1-positive cells
decreasesafterPMAtreatment(Supporting InformationFigS6C,
CD133; see also Fig 6C).
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Figure 3. Release of prominin-1-containing membrane vesicles concomitant with haematopoietic stem cell differentiation.
A. Differential centrifugation of conditioned HSPC/MSC media recovered after either 4, 9 or 14 days in culture as in Fig 1A. The resulting pellets were analysed by
immunoblotting for prominin-1 (arrow) using mAb 80B258 and quantified.
B. Ratioofprominin-1-immunoreactivityfound inthe200,000 gpellet (vesicles) versusthe300 gpellet(cells)wereplottedforthe4,9and14daysofculture
(left y-axis; blue). Total number of haematopoietic cells and prominin-1-positive HSPCs present in culture after 4, 9 and 14 days were indicated in the right y-
axes, green and red, respectively (n¼4). The number of prominin-1-positive cells was calculated by multiplying the percentage of prominin-1-positive cells
(observed by FACS analysis) with the total number of cells. Note that the general proliferation of prominin-1-positive HSPCs stops after 9 days in culture.
C. Summaryofthedifferentconditions.ConditionedmediafromHSPCsgrowingonMSCswererecoveredafter5(conditions4–9or9–14)or10(conditions0–9or
4–14) days in culture. The new medium was added to day 0 (plating day; condition 0–9) or to the 4- (conditions 4–9 and 4–14) or 9- (condition 9–14) days old
cultured cells.
D. Differential centrifugation of conditioned media obtained from the four culture conditions described in (C). The resulting pellets were analysed asi n( A ) .
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tiationwecouldobservetwophenomenabyindirect(differential)
immunoﬂuorescence microscopy for prominin-1 (Fig 6). First, in
somecells,thecellsurfacepoolofprominin-1isslightlyincreased
(Fig 6A, PMA, left panel, red), which was quantiﬁed using ﬂow
cytometry by an increase of median ﬂuorescence intensity (MFI;
Fig 6C). The contact of multivesicular bodies with the plasma
membrane might explain this phenomenon. Second, the
intracellular pool of prominin-1 was signiﬁcantly depleted
(Fig 6A, PMA, green) in comparison to the untreated ones
(Fig6A,control,green)asquantiﬁedbyanetreductionoftheratio
intracellular versus surface staining (Fig 6D). Such events were
also observed after only 1 day of PMA treatment (Fig 6B and D).
These observations are in line with early data showing the
release of exosomes upon phorbol ester treatment of Daudi cells
(Clayton et al, 2001). Collectively, the present data indicate that
the stem cell marker prominin-1 is released and/or degraded by
HSPCs concomitant with their differentiation.
Prominin-1-containing membrane vesicles are transferred to
feeder cells
It becomes more and more evident that exosome-like vesicles
released by various cell types can mediate the transfer of
biochemical information between cells (Simons & Raposo,
2009). Do prominin-1-CMV shuttle between cells? Technically,
we have addressed the latter issue by labelling the prominin-1-
CMV with a membrane dye and following their potential uptake
by either MSCs or HSPCs. Interestingly, after 6h of incubation
we could observe DiO-labelled prominin-1-CMV inside MSCs
where they partly co-localized with SARA indicating their
intracellular delivery to the endosomal compartment of
recipient cells (Fig 7, top panels). Such internalization was
not observed after 1h of incubation as DiO-labelled-vesicles
were detected solely at the cell surface of hosts (Fig 7, middle
panels). Surprisingly, we could not observe such phenomenon
with neighbouring HSPCs as recipient cells suggesting the
selectivity of the transfer processes (Fig 7, bottom panels,
asterisks). However, we could not formally exclude that in the
latter cell type a rapid degradation of prominin-1-CMV occurs.
DISCUSSION
Intriguingly, we demonstrated that, in contrast to other
prominin-1-expressing cell types studied so far, e.g. epithelial
cells (Karbanova ´ et al, 2008; Weigmann et al, 1997), HSPCs
containanimportantintracellularpoolofprominin-1inaddition
to the cell surface one. Inside the cell, prominin-1 is located
primarily in membrane vesicles within multivesicular bodies.
The exosomal localization of prominin-1 is supported by (i) its
presence in low-buoyant density sucrose fractions (1.05–1.15g/ml)
as reported for exosomes (The ´ry et al, 2002), (ii) its partial co-
localization with CD63, (iii) electron microscopic analysis
and (iv) the presence of the exosomal markers ﬂotillins and
syntenin in prominin-1-CMV. Few reports have mentioned the
presence of prominin-1 within the intracytoplasmic compart-
ment of cancerous and/or transformed cells such as adeno-
carcinoma-derived epithelial Caco-2 cells (Corbeil et al, 2000;
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Figure 4. Expression of prominin-1 versus either CD61 or CD42b.
A,B. Flow cytometric analysis revealed phenotypes of HSPCs cultured for 1 week on MSCs for the expression of prominin-1 (CD133) versus either CD61 (A) or
CD42b(B).Thegatesweresetaccordingtounstainedcellsandisotypecontrols(leftpanels).TheamountofCD133-bright,-dim and-negativecellpopulation
is shown as a percentage of the whole CD61- or CD42b-positive population (right panels).
C. The percentageofcellsharbouringthedifferentiationmarkersCD61andCD42bincreasedconcomitantwiththedecreasein prominin-1 (CD133)expression,
resolving that they are mainly expressed on prominin-1-negative cell population. Data obtained from two independent experiments are shown.
www.embomolmed.org EMBO Mol Med 3, 398–409  2011 EMBO Molecular Medicine 403Immervoll et al, 2008). The latter example is particularly
interesting since the release of prominin-1-CMV from these cells
has been reported solely during the process of and upon
differentiation (Marzesco et al, 2005) by a mechanism involving
lipid rafts (Marzesco et al, 2009). Given that HSPCs harbour few
microvillar-like structures in contrast to epithelial cells such as
neural progenitors (Corbeil et al, 2000; Weigmann et al, 1997),
but numerous multivesicular bodies, the endocytic–exocytic
pathway may represent the major way for the release of
prominin-1 in non-epithelial stem and progenitor cells.
Inagreementwiththedetergent-resistanceextractionobserved
for prominin-1 within released membrane vesicles as well as the
lipid raft—association of two other molecules found therein, i.e.
ﬂotillin-1 and ﬂotillin-2 (de Gassart et al, 2003; Rajendran et al,
2003; Salzer & Prohaska, 2001; Staubach et al, 2009), it appears
that speciﬁc lipid–protein interactions might act as a platform for
either the exosomal targeting or the extracellular release of the
prominin-1-containing exosomes. Both scenarios are not
mutually exclusive, and the direct interaction of prominin-1
withmembrane Chis consistentwithit (Ro ¨per etal, 2000).These
observations are coherent with recent data demonstrating that
lipid rafts may participate in the exosomal protein sorting
independently of endosomal sorting complex required for
transport (ESCRT) machinery (Trajkovic et al, 2008). A full
molecular characterization of prominin-1-containing exosomes
described here and determination of exosomal targeting
mechanism(s) of prominin-1 should answer these open issues.
Takentogether,thereleaseofprominin-1-containing exosomes
concomitant with cellular differentiation may represent an
alternative mechanism of externalization of stem/progenitor
properties-containing lipid rafts, in addition to the budding
mechanism underlying the release of prominin-1 from plasma
membrane protrusions (i.e. microvillus and primary cilium) of
neural progenitors (Corbeil et al, 2010; Dubreuil et al, 2007;
Marzescoetal,2005,2009).Thus,theconceptof‘stemcell-speciﬁc
lipid rafts’ holding molecular determinants necessary to maintain
the stem cell properties is attractive in this context (Fargeas et al,
2006; Marzesco et al, 2005) and the characterization of those
containing prominin-1 including their proteome and lipidome
may reveal new aspects of stem cell biology. Along the same line,
it will be of interest to determine whether similar phenomena
occur in cancerous tissues [other than the brain (Huttner et al,
2008)] given that the expression of prominin-1 is often associated
with transformed, treatment-resistant cells exhibiting tumour-
initiating properties (Bao et al, 2006; Liu et al, 2006).
Lastly, we could demonstrate the internalization of prominin-
1-CMV by feeder cells suggesting an additional function in
intercellular communication either by stimulating target cells as
signalling devices via cell surface expressed ligands or by
transferringsurfacereceptors/adhesion moleculesorsmallRNA
between cells (Bakhti et al, 2011; Eldh et al, 2010; Janowska-
Wieczorek et al, 2001; Ratajczak et al, 2006). Such a
phenomenon is in line with exosome-like vesicles acting as
vesicular carriers for intercellular communication (Simons &
Raposo,2009; The ´ryetal, 2009). Again,additional investigation
is urged to reveal whether prominin-1-CMV modify the
biochemistry of the recipient MSCs (Freund et al, 2010) as it
was elegantly proposed upon the direct contact of HSPCs with
osteoblasts (Gillette et al, 2009). Thus, the intercellular
communication of HSPCs with their bone marrow microenvir-
onment is a novel research ﬁeld that requires further
investigation (Me ´ndez-Ferrer et al, 2010) and the development
of animal models to demonstrate its in vivo impact.
In conclusion, we have highlighted that during the process of
differentiation, HSPCs release prominin-1-CMV, which are then
internalized by feeder cells.
MATERIALS AND METHODS
Primary cells and cultivation
Primary HSPCs and MSCs were collected from healthy donors after
informed consent and approval of the local ethics committee. The
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Figure 5. Provoked differentiation stimulated prominin-1-containing
membrane vesicle release.
A,B. HSPCspre-culturedeitheronMSCsorfibronectin-coateddishesfor2days
were incubated in the absence (A) or presence (B) of PMA. After 3 days,
conditioned media were subjected to differential centrifugation as in
Fig 1A. The resulting pellets were analysed by immunoblotting for pro-
minin-1, actin and a-tubulin. Note that only 1/3 of materials were loaded
for the 300 g fraction. The amount of prominin-1 immunoreactive
materialswasquantified[n¼3(MSCs)and4(fibronectin)].Resultsarethe
mean SEM. Ratio of prominin-1-immunoreactivity found in the
200,000 g pellet (vesicles) versus 300 g (cells) is indicated in bracket.
Note that the provoked HSPC differentiation triggered by PMA resulted in
an increase of prominin-1 in 200,000 g pellets, which are devoid of
cytoskeletal proteins under both culture conditions.
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2006). CD34þ MACS-immuno-isolated HSPCs from leukapheresis
products were cultured on MSCs growing on various supports in
serum-free medium supplemented with early acting cytokines (stem
cell factor, foetal liver tyrosine kinase-3 ligand and interleukin-3; IL-3).
Unless otherwise stated, HSPCs/MSCs were incubated at 378Ci na
humidified 5% CO2 atmosphere for 7 days before use. For the PMA
treatment, HSPCs pre-cultured for 2 days on either MSCs or directly on
fibronectin-coated six-well plates were incubated in medium contain-
ing 160nM of PMA for 3 additional days. Alternatively, HSPCs were
pre-cultured for 4 days before 1 day of PMA treatment.
Differential centrifugation and detergent lysis
Conditioned HSPC/MSC medium was subjected to differential centrifu-
gation as follows: 5min at 300 g; supernatant, 20min at 1200 g;
supernatant, 30min at 10,000 g; supernatant, 1h at 200,000 g;
supernatant and 1h at 400,000 g. The resulting pellets were
resuspended in Laemmli buffer and analysed by immunoblotting. An
aliquot (1/10th) of the 400,000 g supernatant was analysed in
parallel. In some experiments, HSPCs and the 200,000 g pellet
recovered after differential centrifugation were lysed for 30min in ice-
cold buffer A (150mM NaCl, 2mM EGTA, 50mM Tris–HCl pH 7.5,
10mg/ml aprotinin, 2mg/ml leupeptin and 1mM PMSF) containing
either 0.5% Triton X-100 or Lubrol WX (Serva). Detergent lysates were
centrifuged at 48C for 1h at 100,000 g. The entire supernatant and
pellet were analysed by immunoblotting.
Sucrose gradient centrifugation
The 200,000 g pellet was resuspended in phosphate buffered saline
(PBS) containing 1mM CaCl2, 0.5mM MgCl2 and protease inhibitors
(Complete, Roche Diagnostics), placed on top of a equilibrium sucrose
gradient (0.1–1.2M) and centrifuged at 65,000 g for 5h (Huttner et
al, 1983). After centrifugation, 500ml fractions were collected from
the top to the bottom of the gradient and the pellet was resuspended
in 500ml buffer A containing 1% Triton X-100. Four hundred and fifty
microlitres of aliquots of each fraction were concentrated using
methanol/chloroform precipitation and analysed by immunoblotting.
The remaining 50-ml aliquot of each fraction was used to determine
the sucrose concentration by refractive index.
Immuno-isolation of prominin-1-containing membrane
vesicles
The immuno-isolation of prominin-1-CMV was performed using
immunomagnetic beads (Miltenyi Biotec, Bergisch Gladbach, Ger-
many). The conditioned medium collected from either HSPCs growing
on MSCs or, as control, MSCs alone was centrifuged at 1200 g for
20min to remove cells. Supernatants were concentrated to 400mlb y
Centricon PL-30 (Millipore Corp., Belford, MA) and 400ml of ice-cold
PBS were added followed by centrifugation at 10,000 g for 30min.
The 10,000 g supernatants were pre-incubated with goat-anti-
mouse IgG-magnetic-beads (Miltenyi Biotec) for 1.5h at 48C. The
supernatants were then applied to ice-cold PBS conditioned MS-
columns (Miltenyi Biotec) placed into a magnetic field, and the flow-
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Figure 6. Intracellular pool of prominin-1 is
depleted upon PMA treatment.
A,B. HSPCs pre-cultured on MSCs for 2 days were
incubated in the absence (control) or presence
of phorbol ester PMA (PMA). After 3 (A) or 1 (B)
days, cells were first cell surface-labelled for
prominin-1 (red) prior to PFA-fixation and
saponin-permeabilizationfollowedby asecond
round of prominin-1 (green) labelling. The
nuclei were stained with DAPI (blue). The
labelled cells were analysed using confocal
laser-scanning microscopy. A single optical
x–y-plane section is shown. Scale bar, 5mm [(A)
and (B)].
C. After 3 days of incubation without (left panel)
or with (right panel) PMA the number (indi-
cated above the bar) of prominin-1-positive
cells (open areas) was reduced, whereas, the
MFI was slightly increased as analysed by flow
cytometry. Appropriate isotype-matching con-
trol is depicted (grey filled areas).
D. The ratio of intracellular (I) versus cell surface
(S) fluorescence intensity of prominin-1 was
quantified using CellProfiler 2.0 software.
Results are themean SEM. (n¼60cells; three
independent donors). Note the reduction of the
intracellular pool of prominin-1 upon 1 or 3
days (D) of PMA treatment.
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fraction and the control fraction were then incubated each with
mouse mAb CD133-magnetic-beads (Miltenyi Biotec).The other half of
HSPC/MSC medium fraction was incubated with goat anti-mouse IgG-
magnetic-beads as an additional control. After 1h incubation, samples
were subjected to a magnetic separation. Vesicles retained in the MS-
columns were eluted by taking out the column from the magnet, and
flushing with PBS. Laemmli buffer (4 ) was added and the samples
were stored at  208C. The recovered flow-through fractions were
centrifuged at 200,000 g for 1h to obtain the unbound materials,
which were resuspended in Laemmli buffer and stored at  208C.
SDS–PAGE and immunoblotting
Proteins were analysed by SDS–PAGE and transferred to poly(viny-
lidene difluoride) membranes (Millipore Corp.; Corbeil et al, 2001).
Immunoblotting was performed using distinct primary antibodies
followed by appropriate horseradish peroxidase-conjugated second-
ary antibody. Immune complexes were detected using enhanced
chemiluminescence (Amersham Biosciences) and quantified after
scanning the Hyperfilm (Amersham) using the MacBas or ImageJ
software.
Radioactive labelling, lipid extraction and thin layer
chromatography
Six-days-old HSPCs cultured on MSCs were collected and centrifuged
at 1200 g for 5min. Cells were resuspended and replated onto the
same MSCs in fresh HSPC medium containing 10mCiC
14/100-mm
Petri dish. The cells were cultured for 3 additional days. Lipids from
haematopoietic cells and immunomagnetic-isolated prominin-1-CMV
were extracted as follows: cells and the prominin-1-containing vesicle
fractions were each put into 2ml of MeOH/CHCl3 (2:1), mixed, and
centrifuged for 5min at 3200 g. The supernatants were transferred
to a fresh tube, to which 0.5ml of 20mM acetic acid and 0.5ml of
CHCl3 were added, mixed and centrifuged again for 2min at 3200 g.
The lower phase was transferred to another tube, while 25mlo f1M
citric acid and 1ml of CHCl3 were added to the upper phase, mixed
and centrifuged for 2min at 3200 g. The lower phase was
transferred to the same tube as the previous lower phase and the
CHCl3 was evaporated under a stream of nitrogen. Dried lipids were
dissolved in MeOH/CHCl3 (1:2) and applied to silica TLC plates (Merck)
using a capillary. To separate the lipids, the plates were run in
chloroform/ethanol/water/triethylamine (35:50:10:35) until 2:3 of the
distance, then the plates were dried and subsequently placed and run
in iso-hexane/ethylacetate (5:1) for the full distance and dried again.
TLC plates were exposed to image plates (Fuji), which were analysed
by the BAS 1800 II phosphoimager. Bands were identified by
comparison with lipid standards and quantified using ImageGauge
V4.23.
Immunofluorescence and confocal microscopy
One-week-old co-cultured HSPCs/MSCs were gently washed with PBS,
fixed with 4% paraformaldehyde (PFA), quenched with 50mM NH4Cl
and then permeabilized with 0.2% saponin in blocking buffer (PBS
containing 2% foetal calf serum; FCS). Cells were sequentially
incubated for 30min with mouse mAb CD133/1 (anti-prominin-1;
Miltenyi Biotec) at room temperature (RT) followed by 1h incubation
with Cy
TM3-conjugated AffiniPure donkey-a-mouse IgG (HþL) Fab
fragment (Jackson ImmunoResearch Laboratories) at 48C. Remaining
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Figure 7. Internalization of prominin-1-
containing membrane vesicles by feeder cells.
A,B,C. Immuno-isolated prominin-1-CMV were
labelled with the membrane dye DiO (green),
and then incubated with HSPC/MSC co-
culture for 6h (A and C) or 1h (B). PFA-fixed,
saponin-permeabilized cells were immuno-
labelled for Smad anchor for receptor acti-
vation protein (SARA; red). Nuclei were
visualized with DAPI (blue). The labelled cells
were analysed using confocal laser-scanning
microscopy. Single optical x–y-plane sections
(A and B; DAPI and SARA) or composite of >10
sections (A and B, merge panels; C) are shown.
The position of x–z sections is indicated by
white lines in the corresponding panel. Insets
(A and B) are displayed either in double (left)
or single (right) channel. Open arrowheads,
prominin-1-CMV; filled arrowheads, double-
positive (prominin-1-CMV, SARA) structures;
asterisks, HSPCs. Scale bars, 10mm [(A–C)],
1mm [(A, inset), (B, inset)].
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AffiniPure rabbit-a-mouse IgG (HþL) Fab fragment (Jackson Im-
munoResearch). After a post-fixation step with 0.2% PFA and
quenching, cells were incubated for 30min with mouse mAb MX-
49.129.5 (anti-CD63; Santa Cruz Biotechnology) followed by Cy
TM2-
conjugated goat-a-mouse antibody IgG (HþL; Jackson ImmunoR-
esearch) at RT. In the case of cell surface versus intracellular labelling,
cells were first cell surface labelled with mAb CD133/1 in the cold
prior fixation, as described (Corbeil et al, 1999), followed by the
saturation of remaining mouse epitopes with unconjugated AffiniPure
rabbit-a-mouse IgG (HþL) Fab fragment. Afterward, cells were post-
PFA-fixed, saponin-permeabilized and finally labelled with mAb
CD133/1 as described above for anti-CD63. Alternatively, fixed,
saponin-permeabilized cells were sequentially incubated for 30min
at RTwith mouse mAb CD133/1 alone or with either sheep antiserum
against TGN46 (Serotec) or rabbit antiserum against GM130 (Abcam)
or rabbit antiserum against SARA (Santa Cruz Biotechnology) or rabbit
antiserum against EEA1 (a generous gift from Marino Zerial, MPI-CBG)
followed by appropriate secondary antibodies; Cy
TM2/3-conjugated
goat anti-mouse IgG (HþL) alone or with either Cy
TM2-conjugated
donkey anti-sheep IgG (HþL) or Cy
TM2/3-conjugated goat anti-rabbit
IgG (HþL; Jackson ImmunoResearch). Alternatively, CD133-labelled
cells were co-stained with BODIPY 493/503 (Invitrogen Molecular
Probes, USA).
In all cases, nuclei were labelled with either Hoechst 33258
(Invitrogen, Karlsruhe, Germany) or 4,6-diamidino-2-phenylindole
(DAPI; Molecular Probes). The cells were mounted in Mowiol 4.88.
Images were captured using confocal microscope. The images shown
were prepared from the confocal data files using Adobe Photoshop
software. Ratio of intracellular versus surface immunofluorescence of
prominin-1 was calculated from total image pixel intensity using
CellProfiler 2.0 software (Broad Institute, Cambridge, MA).
Immunoelectron microscopy
Membrane vesicles—The 200,000 g pellet was resuspended in 4%
PFA in phosphate buffer and applied onto 400-mesh grids with
formvar- and carbon-coating. The samples were blocked with 0.1%
glycin in PBS and twice with 0.2% gelatine, 0.5% bovine serum
albumin in PBS (PBG). The grids were incubated with either mAb
AC141 (Miltenyi Biotec) directed against human prominin-1 or mAb
PeliCluster CD63 (Sanquin) followed by goat anti-mouse IgG coupled
to 10-nm gold (British Biocell). The grids were post-fixed in 2%
glutaraldehyde (GA) in PBS, negatively contrasted and viewed in a
Morgagni electron microscope (FEI Company). Micrographs were
taken with a MegaviewII camera and AnalySIS software (Soft Imaging
Systems).
HSPCs—HSPC/MSC co-cultures grown on Transwell filters were fixed
with 4% PFA in PBS, quenched and then permeabilized and blocked
with 0.2% saponin, 2% FCS in PBS (blocking solution). Cells were
incubated with mAb CD133/1 followed by goat anti-mouse secondary
antibody coupled to ultra-small gold (Aurion, Wageningen, The
Netherlands). Filters were rinsed sequentially with blocking solution
and PBS followed by fixation in 2% GA. The samples were processed
for silver enhancement using R-GENT SE-EM silver enhancement kit
(Aurion) prior to post-fixation in 1% osmium tetroxide. Dehydration
was performed by a graded series of ethanol. Samples were infiltrated
in EMBed resin (Science Services). Ultrathin sections were cut on a UCT
ultra-microtome (Leica Microsystems) and post-stained with uranyl
acetate and lead citrate. For the CD63 labelling, ultrathin cryosections
were prepared as described (Dubreuil et al, 2007), and immunola-
belled with mAb PeliCluster CD63.
Flow cytometry
HSPCs recovered by centrifugation were processed for flow cytometry
using various antibodies (see Materials and Methods Section of
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The paper explained
PROBLEM:
The process of cell differentiation is a central issue in stem cell
biology and understanding its mechanism might allow us to
manipulate the fate of stem cells opening novel avenues
for stem cell-based therapies. It is equally important to
understand all cellular events occurring within the stem cell
niche including intercellular communication. Here, we have
addressed these issues by tracking the transport of the
stem cell marker prominin-1. The medical interest in this
molecule has grown extremely rapidly since its cell surface
appearance allows the isolation of stem cells from various
organs including those derived from haematopoietic and
neural systems.
RESULTS:
Using an ex vivo co-culture system consisting of human primary
HSPCs growing on multipotent MSCs as a feeder cell layer, we
describe that during the process of differentiation, the
haematopoietic progenitors release small membrane vesicles
containing prominin-1 by exportation via exosomes. Upon
release, prominin-1-containing membrane vesicles are inter-
nalized by feeder cells.
IMPACT:
We have highlighted the role of the endocytic–exocytic pathway
in the release of prominin-1, which occurs concomitantly with
cellular differentiation. Such valuable information might help us
in the near future to modulate the fate of rare stem cells (e.g.
those derived from cord blood), which are clinically important.
Moreover, our observations provide evidence for the intercellular
communication between stem cells and their supporting feeder
cells, which opens a novel research field that requires further
investigation.
www.embomolmed.org EMBO Mol Med 3, 398–409  2011 EMBO Molecular Medicine 407Supporting Information). Samples were analysed by acquiring 10,000
events on a FACS LSR II (BD Biosciences). Instrument settings and
gating strategies were established using appropriate controls, and
data were analysed using either DIVA software (BD Biosciences) or
FlowJo software (TreeStar, Ashland, USA).
Double labelling of HSPCs for annexin V and prominin-1
HSPCs recovered by centrifugation were incubated with annexin
V-APC (BD Bioscience), fixed with 4% PFA, quenched and blocked
with blocking buffer (see above). Cells were labelled with mAb
CD133/1 followed by incubation with Cy
TM3-conjugated goat anti-
mouse IgG (HþL). Nuclei were visualized with Hoechst 33258. Cells
were mounted in Mowiol 4.88 and observed on a Zeiss LSM 510 Meta
microscope. The numbers of annexin V-positive cells, CD133-positive
and double-positive cells were scored.
Internalization of prominin-1-containing membrane vesicles
The materials recovered in 200,000 g fraction were resuspended in
PBS and incubated with 3,30-dioctadecyloxacarbocyanine perchlorate
(DiO; Vybrant Cell-Labeling Solution, Molecular Probes). Afterward,
DiO-labelled vesicles were immuno-isolated based on prominin-1 as
described above. Isolated DiO-labelled prominin-1-CMV were incu-
bated either for 1 or 6h with co-cultured HSPCs/MSCs growing on
fibronectin-coated coverslips. Samples were processed for immuno-
fluorescence for SARA, and observed using a Leica SP5 upright confocal
microscope.
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